Better Therapeutics to Host Virtual Educational Webinar Symposium on New American Diabetes Association Guidelines Recommending Digital Tools in Diabetes Care
Leading Medical Experts to Discuss Promising Developments on Prescription Digital Therapeutics and Nutritional Cognitive Behavioral Therapy for Type 2 Diabetes Patients
WHAT: The online symposium will convene a panel of experts to review the new
The panel will review and discuss recently released clinical trial data from Better Therapeutics’ pivotal clinical trial for BT-001, its digital therapeutic platform for type 2 diabetes. Released earlier this year, the clinical trial demonstrated significant reduction in A1c levels that surpassed results seen in patients using pharmaceutical solutions alone.
The symposium will also discuss the future potential for prescription digital therapeutics to address the ADA’s behavior change guidelines and to improve type 2 diabetes patient outcomes.
Marc Bonaca, MD, MPH, Professor of Medicine and Director of Vascular Research, University of Colorado
Bob Eckel, MD, Professor of Medicine, University of Coloradoand past president of American Heart Associationand American Diabetes Association
Judy Hsia, MD, Research Professor of Medicine, University of Colorado
Panel and Presenters:
Hayden Bosworth, PhD, Research Professor, Department of Medicine, Division of General Internal Medicine, Department of Psychiatry and Behavioral Sciences, School of Nursing, Duke University Medical Center
Amy Bucher, PhD, Chief Behavioral Officer, Lirio
Prapti Mehta, MD, Private Practice Psychiatrist, San Francisco, California
Kristin Wynholds, Chief Product Officer, Better Therapeutics
WHERE: To attend the webinar, please register at: bit.ly/3wpwBWA
For more information visit: bettertx.com
Certain statements made in this press release are "forward-looking statements" within the meaning of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are typically identified by words such as “plan,” “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “should,” “would” and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements in this press release include, but are not limited to, statements regarding the timing and results of the ongoing trial of BT-001 in patients with type 2 diabetes, Better Therapeutics’ plans regarding FDA submissions, expectations related to the potential benefits of BT-001 and CBT and their potential treatment applications, Better Therapeutics’ plans regarding the research and advancement of its product candidates for additional treatments, expectations related to the interest of healthcare providers and payers in PDTs and legislative developments affecting PDTs and the outcome of such developments, among others. These forward-looking statements are based on the current expectations of the management of